Skip to main content
Clinical Trials/EUCTR2008-001136-12-IT
EUCTR2008-001136-12-IT
Active, Not Recruiting
N/A

ONG-TERM OXYGEN THERAPY (LTOT) IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS WITH MODERATE CHRONIC HYPOXEMIA AND CHRONIC HEART FAILURE - LTOT IN COPD WITH CHRONIC HYPOXEMIA AND CHF

AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI0 sitesJune 5, 2008

Overview

Phase
N/A
Intervention
Not specified
Conditions
COPD patients with moderate chronic stable hypoxemia and chronic heart failure.
Sponsor
AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI
Status
Active, Not Recruiting
Last Updated
14 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 5, 2008
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI

Eligibility Criteria

Inclusion Criteria

  • A patient will be eligible for inclusion in this study if all of the following criteria are met: 1\. Male or female outpatients, aged 40\-80 years inclusive, with a baseline post\-bronchodilator FEV1 \<80% of predicted normal, and post\-bronchodilator FEV1/VC\<70%. 2\. An established clinical history of COPD according to the GOLD (5\) 3\. Moderate and stable chronic hypoxemia at rest (55\< PaO2\<65 mmHg) detected on 5 measurements separated by at least 2 weeks 4\. Clinical signs of chronic heart failure according to the European Society of Cardiology (ESC) criteria (16\), as certified by the local cardiology specialist 5\. Ex smokers with \> 20 pk/years having stopped for at least 3 months
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • Patients will be excluded from the study if they have: 1\.congenital heart disease, 2\.lung cancer, or other cancers, 3\.restrictive disorder (e.g. tuberculosis sequelae, interstitial pulmonary diseases); 4\. other clinically significant coexisting severe diseases that could influence the survival in the study period.

Outcomes

Primary Outcomes

Not specified

Similar Trials